B4GALT1
B4GALT1 (Beta-1,4-galactosyltransferase 1) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.
Overview
Galactosyltransferase acting in the Golgi stacks. Catalyses the transfer of galactose (Gal) from UDP-alpha-D-galactose in beta(1->4) linkage to the non-reducing terminal N-acetylglucosamine (GlcNAc) moieties of glycolipids and complex-type N-linked glycans. Adds one Gal residue to both GlcNAc beta(1->2)-linked to the alpha(1->3) and alpha(1->6) mannose antennae of complex-type N-glycans, enabling the formation of mono- and di-galactosylated glycoforms.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · B4GALT1 (Beta-1,4-galactosyltransferase 1) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.
- 1 · What it is
B4GALT1 (Beta-1,4-galactosyltransferase 1) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.
- 2 · What goes wrong in cancer
Galactosyltransferase acting in the Golgi stacks.
- 3 · How drugs use it
No product in this corpus aims at B4GALT1 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:924 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P15291 (protein name, function text, keywords and locations (REST API)); CIViC gene B4GALT1 (1 evidence items, 0 assertions, 1 variants; diseases: Renal Cell Carcinoma (GraphQL API, CC0))
Biology
Galactosyltransferase acting in the Golgi stacks. Catalyses the transfer of galactose (Gal) from UDP-alpha-D-galactose in beta(1->4) linkage to the non-reducing terminal N-acetylglucosamine (GlcNAc) moieties of glycolipids and complex-type N-linked glycans. Adds one Gal residue to both GlcNAc beta(1->2)-linked to the alpha(1->3) and alpha(1->6) mannose antennae of complex-type N-glycans, enabling the formation of mono- and di-galactosylated glycoforms. Galactosylates complex-type N-glycans attached on the fragment crystallizable (Fc) of immunoglobulin-gamma isotypes (IgGs), a prerequisite for antibody glycan sialylation and related anti-inflammatory effector functions. Can also transfer a Gal residue to free GlcNAc to form N-acetyllactosamine. With LALBA/alpha-lactalbumin forms the lactose synthase complex responsible for production of large amounts of lactose in the lactating mammary gland. Location: Golgi apparatus, Golgi stack membrane; Cell membrane; Cell surface; Cell projection, filopodium (UniProt). Locus 9p21.1 (HGNC).
- Renal cell carcinoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"B4GALT1" OR ABSTRACT:"B4GALT1" OR TITLE:"beta-1,4-galactosyltransferase 1" OR ABSTRACT:"beta-1,4-galactosyltransferase 1" OR TITLE:"Beta-1,4-galactosyltransferase 1" OR ABSTRACT:"Beta-1,4-galactosyltransferase 1" OR TITLE:"beta4Gal-T1" OR ABSTRACT:"beta4Gal-T1" OR TITLE:"GGTB2" OR ABSTRACT:"GGTB2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about B4GALT1, not a curated reading list.